2013-08-27 11:53:35 - Recently published research from GlobalData, "EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022", is now available at Fast Market Research
Nonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. NASH is becoming increasingly common with the alarming epidemic of obesity. As obesity is a major risk factor for other metabolic syndrome diseases, such as type 2 diabetes and dyslipidemia, the incorporation of weights from the age- and sex-specific prevalence of obesity in each of the 6MM adds granularity to the forecast analysis, which allowed GlobalData epidemiologists to provide a comprehensive forecast of the prevalent cases of NASH in the 6MM.
GlobalData's epidemiological analysis forecasts that prevalent cases of NASH in the 6MM (US,
France, Germany, Italy, Spain, and UK) will grow by 8.24% over the next decade, from 29.38 million prevalent cases in 2012 to 31.80 million prevalent cases in 2022. The US and Germany will continue to have the highest number of prevalent cases in the 6MM during 2012-2022. The US will have 48.29% (15.36 million cases) of all prevalent cases in the 6MM in 2022, with the second largest annual growth rate (AGR) of 1.03% throughout the forecast period. Changes in the definition of nonalcoholic, which is the basis for defining NASH cases, the development of less invasive gold-standard diagnostic methods for NASH, and changes in the prevalence of the metabolic syndrome will influence the prevalence of NAFLD and NASH during the forecast period.
Full Report Details at
- www.fastmr.com/prod/671260_epicast_report_nonalcoholic_steatohep ..
* The Nonalcoholic Steatohepatitis (NASH) EpiCast Report provides an overview of the risk factors and global trends of NASH in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of NASH prevalent cases segmented by age (in five-year increments beginning at age 20 and ending at age =85 years) and sex in the 6MM.
* The NASH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to Get this Report
* Develop business strategies by understanding the trends shaping and driving the global NASH market.
* Quantify patient populations in the global NASH market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
Report Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality
3.2.2 Being a male is an independent risk factor in morbidly obese NASH cases
3.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH
3.3 Global Trends
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Forecast Assumptions and Methods
3.4.3 Sources Not Used
3.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012-2022)
3.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis
3.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis
3.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis
3.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis
3.6.1 Conclusions on Epidemiological Trends
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Epidemiology and Health Policy
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
List of Tables
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for NASH
Table 2: Reported Prevalence of NASH in the US and 5EU
Table 3: Reported Prevalence of NAFLD in the US and 5EU
Table 4: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast
Table 5: 6MM, Prevalent Cases of NASH, Ages ≥20 Years, Men and Women, N, Selected Years, 2012-2022
Table 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012
Table 7: 6MM, Prevalent Cases of NASH, Ages ≥20 Years, By Sex, N (Row %), 2012
List of Figures
1.2 List of Figures
Figure 1: 5EU, Prevalence of NAFLD and Obesity, Ages ≥20 Years, Men and Women, %
Figure 2: 6MM, Prevalent Cases of NASH, Ages ≥20 Years, Men and Women, N, Selected Years, 2012-2022
Figure 3: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012
Figure 4: 6MM, Prevalent Cases of NASH, Ages ≥20 Years, By Sex, N, 2012
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.